欧洲碳青霉烯类抗生素市场预测至 2028 年 - COVID-19 影响和区域分析（按类型（美罗培南、多尼培南、亚胺培南、替比培南等）、适应症（细菌性脑膜炎、急性盆腔感染、呼吸道感染、腹内感染、尿路感染等）和分销渠道（零售药店、网上药店、医院药房）
No. of Pages: 153 | Report Code: TIPRE00028790 | Category: Life Sciences
No. of Pages: 153 | Report Code: TIPRE00028790 | Category: Life Sciences
市场的增长归因于流行率上升等因素细菌感染和增加领先制药企业的私人和公共伙伴关系。然而，繁琐且昂贵的抗生素开发过程预计将在预测期内限制市场的增长。
抗菌素耐药性（AMR）已成为全球的重大威胁。由于接触抗生素和自发突变等环境因素，细菌对许多抗生素变得高度耐药。因此，设计了各种策略来测量和控制抗菌素耐药性的传播。一些政府和医疗机构实施了建设性计划来应对这种危急情况。 2017年，德国政府宣布启动全球研发合作中心，反对AMR专注于弥合新研发领域的差距。 2019年1月，英国政府启动了应对抗菌素耐药性战略。英国政府制定了一项应对抗菌素耐药性的五年国家行动计划。此外，它还制定了到 2040 年降低抗菌素耐药性的愿景。该计划是在苏格兰、威尔士和北爱尔兰等政府及其机构和行政部门在一系列利益相关者的支持下制定的。
2020 年 4 月，Venatorx Pharmaceuticals 和全球抗生素研究与开发伙伴关系 (GARDP) 宣布合作，加速头孢吡肟-他尼硼巴坦的开发和获取。它是一种广谱β-内酰胺酶抑制剂，可恢复头孢吡肟对抗碳青霉烯类耐药肠杆菌（CRE）和碳青霉烯类耐药铜绿假单胞菌（CRPA）的活性。然而，它是第四代抗生素头孢吡肟与他尼硼巴坦的研究组合。通过合作，GARDP 和 Venatorx 期待开发头孢吡肟-坦尼硼巴坦。该组合正在进行 3 期 cUTI 试验。此外，正在对患有多重耐药感染的成人进行临床试验，并开展临床开发活动，以及为儿童（包括患有严重细菌感染的新生儿）使用头孢吡肟-坦尼硼巴坦的试验。预计公共和私人合作伙伴的此类活动将为预测期内碳青霉烯类抗生素市场的增长提供利润丰厚的机会。
Strategic insights for Europe Carbapenem-Based Antibiotics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,128.37 Million |
| Market Size by 2028 | US$ 1,469.86 Million |
| Global CAGR (2021 - 2028) | 3.8% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Carbapenem-Based Antibiotics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Carbapenem-Based Antibiotics Market is valued at US$ 1,128.37 Million in 2021, it is projected to reach US$ 1,469.86 Million by 2028.
As per our report Europe Carbapenem-Based Antibiotics Market, the market size is valued at US$ 1,128.37 Million in 2021, projecting it to reach US$ 1,469.86 Million by 2028. This translates to a CAGR of approximately 3.8% during the forecast period.
The Europe Carbapenem-Based Antibiotics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Carbapenem-Based Antibiotics Market report:
The Europe Carbapenem-Based Antibiotics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Carbapenem-Based Antibiotics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Carbapenem-Based Antibiotics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Carbapenem-Based Antibiotics Market
